Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy

BACKGROUND: Long-acting muscarinic antagonist/long-acting β(2)-agonist (LAMA/LABA) provide greater improvements in lung function and symptoms than inhaled corticosteroid (ICS)/LABA in patients with chronic obstructive pulmonary disease (COPD). This study evaluated symptom burden and Global Initiativ...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Chron Obstruct Pulmon Dis
Päätekijät: Moretz, Chad, Hahn, Beth, White, John, Goolsby Hunter, Alyssa, Essoi, Breanna, Elliott, Caitlin, Ray, Riju
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7605915/
https://ncbi.nlm.nih.gov/pubmed/33149569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S265037
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia